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TP53 (tumor protein p53; p53) regulates its target genes under various cellular stresses. By combining chromatin immunoprecipitation with
oligonucleotide microarrays, we have mapped binding sites of p53 (p53-BS) in the genome of HCT116 human colon carcinoma cells, along with
those of acetylated H3, acetylated H4, and methylated H3-K4. We analyzed a 30-Mb portion of the human genome selected as a representative
model by the ENCODE Consortium. In the region, we found 37 p53-BS, of which the p53-binding motif was present in 32 (86%). Acetylated
histone H3 and H4 were detected at 14 (38%) and 33 (89%) of the p53-BS, respectively. A significant portion (58%) of H4 acetylation in the
p53-BS was not accompanied by H3 acetylation. Acetyl H3 were preferentially located at the 5′ and 3′ ends of genes, whereas acetyl H4 were
distributed widely across the genome. These results provide novel insights into how p53 binding coordinates with histone modification in
human.
© 2006 Elsevier Inc. All rights reserved.Keywords: TP53 protein; Histone; Chromatin; Oligonucleotide microarrays; HCT116 cells; HumanIntroduction
TP53 (tumor protein p53; Li-Fraumeni syndrome; p53) plays
an important role in the cellular response to various stresses such
as DNA damage and hypoxia, and loss of p53 is associated with
genomic instability and tumor development. The activation of
p53 can lead to cell cycle arrest, apoptosis, or senescence,
depending on the cellular context [1]. A major function of p53 is
that of a transcription factor to control the expression of its target
genes, whose functions fall into categories that reflect the role of
p53 as an integrator of diverse cellular signals [2]. Differential
induction of target genes by p53 is important, particularly in
determining whether a cell is destined for cell cycle arrest or
apoptosis [3]. A number of approaches, including gene
expression profiling and genome-wide sequence analysis, have
identified dozens of p53-regulated genes, including CDKN1A,⁎ Corresponding author.
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doi:10.1016/j.ygeno.2006.09.001MDM2, BAX and BBC3 [4]. However, the mechanism under-
lying p53-regulated transcriptional control has not been fully
elucidated [5].
Among many factors, the physical interaction of the p53
protein with DNA is central to its role in transcriptional
regulation. Target genes of p53 have one or more p53-binding
sites (p53-BS) very similar to the p53 consensus DNA-binding
motif that consists of two copies of the 10 basepair (bp)
sequence 5′-PuPuPuC(A/T) (T/A)GPyPyPy-3′, separated by 0
to 13 bp. However, this rule is not strict and only a few p53-BS
are perfect matches for the p53 consensus DNA-binding motif
[6,7]. Studies examining the in vivo binding of p53 by
chromatin immunoprecipitation (ChIP) have demonstrated
that there are large differences in the kinetics and extent of
p53 binding to target gene promoters [8,9]. There are several
factors that might contribute to differential binding activity of
p53 to target genes. Posttranslational modifications and co-
activators of p53 may regulate its DNA-binding activity [10–
13]. Also, individual sequence differences between p53-BS and
the number of p53-BS might contribute to the differential DNA-
Fig. 1. Transactivation of p53 and p53 binding at the promoter of p21. (A)
Western blot with protein extracts from HCT116 cells treated with 5FU. The
p53-null cells were derived from parental HCT116 by gene targeting. (B)
Chromatin immunoprecipitates from 5FU-treated and untreated HCT116 cells
were analyzed by Q-PCR at the promoter of p21.
179K. Kaneshiro et al. / Genomics 89 (2007) 178–188binding activity of p53 [14,15]. Recently, a genomic map of
p53-BS along human chromosome 21 and 22 was reported [16].
Interestingly, quite a large number of p53-BS were observed in
intronic and intergenic regions as well as the promoters of
genes. How, or even whether, these nongenic sequences
contribute to transcriptional regulation is unclear [17].
Histone tails are thought to be heterogeneously modified
throughout the genome and to specify a code to regulate the
expression of genes [18]. p53-dependent changes in histone
modification have been observed at the promoters of a number of
p53 target genes [19–26]. p53 interacts with components of
multiple different histone remodeling complexes, including CBP/
EP300 (CBP/p300), GCN5, PCAF, and SETD7, and may recruit
them to p53-binding sites on target genes [21,27]. These histone-
modifying enzymes can regulate chromatin structure and function
in part by recruiting additional proteins [18]. Recently it has been
shown that the promoters of p53 target genes have distinctive
patterns of p53-dependent histone acetylation [28]. In the
promoter of CDKN1A, a distinctive behavior of H3 and H4
acetylation has also been reported [29]. These observations raise
the possibility that p53 binding coordinates with histone
modification to regulate transcription. Still, many aspects of
how p53 associates with histone modification in the human
genome remain obscure.
In this report, we describe a large-scale study of p53 binding,
histone modification patterns, and gene expression analysis in
5FU-treated HCT116 human cell lines using 30 Mb (1%) of
nonrepetitive human genome as target. For mapping studies, we
used an unbiased approach combining ChIP, in vitro transcrip-
tion (IVT) amplification, and high-density oligonucleotide
tiling arrays (ChIP-chip). The tiling arrays used here cover 44
discrete genomic regions selected by the ENCyclopedia Of DNA
Elements (ENCODE) Consortium as a representative collection of
genomic features [30]. Thus, our study provides substantial
information on how p53 associates with histone modification in
human.
Results
ChIP for p53 and modified histones
Prior to the ChIP experiment, we tested the transactivation of
p53 in wildtype TP53-containing HCT116 colon carcinoma
cells and TP53-null derivatives. Protein extracts were prepared
from cells treated with a DNA-damaging agent, 5-fluorouracil
(5FU) for 0 to 24 h. The p53 protein level increased after 5FU
treatment for 9 h (Fig. 1A). This increase was accompanied by
the posttranslational modifications of p53 itself and induction of
CDKN1A and MDM2 protein expression, which were not seen
in p53-null cells (Fig. 1A). The induction of CDKN1A and
MDM2 mRNA expression was also seen in p53 wildtype cells
treated with 5FU for 9 h (data not shown).
Next, the ChIP assay was tested for detection of specific
TP53 DNA binding at the promoter of CDKN1A. 5FU-treated
(9 h) and untreated HCT116 cells were treated with formalde-
hyde to form protein–DNA complexes. Chromatin purified
from nuclei was sheared to an average size of 600 bp andimmunoprecipitated with anti-p53 antibody. The cross-links
were reversed and the DNA was purified and analyzed for the
enrichment of a known p53-binding region in the promoter of
CDKN1A, by using quantitative PCR. The amount of
CDKN1A associated p53-binding region increased fourfold in
5FU-treated cells (Fig. 1B). Enrichment of the p53-binding
region was not seen either in TP53-null cells or in negative
controls in which normal mouse IgG was used for chromatin
immunoprecipitation (Fig. 1B).
To test the kinetics of histone acetylation at the promoter of
CDKN1A, we measured the amount of histone acetylation at
the p53-binding region by ChIP using antibodies recognizing
multiple acetylated forms of H3 or H4. In the absence of 5FU,
the level of H4 acetylation was two- to threefold higher in
TP53 wildtype cells than in TP53-null cells (Fig. 1B). After
5FU treatment, there was no change in H4 acetylation in
TP53-null cells, but a five- to sixfold increase in the TP53
wildtype cells (Fig. 1B). H3 acetylation showed a pattern
similar to H4 acetylation (Fig. 1B). These results indicate the
p53 dependency of histone acetylation at the promoter of
CDKN1A.
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We next generated a genomic map of p53 binding in the
human ENCODE region, together with H3 and H4 acetylation
and H3 Lys4 di- and trimethylation. Cross-linked chromatin
from the 5FU-treated (9 h) HCT116 cells was immunoprecipi-
tated with antibodies against p53, H3 Lys9/14 acetylation, H3
Lys4 di- and trimethylation, and H4 Lys5/8/12/16 acetylation.
The immunoprecipitated DNA and untreated control DNA
(whole-cell extract) were amplified by in vitro transcription and
hybridized separately to oligonucleotide arrays that tile
nonrepetitive portions of the human ENCODE region at 22-
bp intervals. Genomic sites enriched for p53 and modified
histone were identified by sliding a 550-bp window across the
regions and testing whether signals of oligonucleotide probes
within the window were significantly greater for the ChIP
sample than for the control. After applying a significance
threshold of p<10−5, we excluded those sites composed of
more than 70% repeat sequences. As shown in Supplemental
Figure 1A, most of the identified sites (77%) contained less than
10% repeat sequences. The identified sites with more than 70%
repeat sequences had enrichment ratios of less than twofold
(data not shown). Considering the limitations of the ChIP-chip
method, it is not surprising that repeat sequences cause false-
positives. For p53, we applied a cutoff combining a significance
threshold and a signal ratio of ChIP/control because this cutoff
gave lower false-positive rates (Supplemental Fig. 1B). Finally,
our analysis identified 40 p53-BS, 512 acetyl H3, 416 acetyl
H4, 541 dimethyl H3, and 275 trimethyl H3 sites with median
size of 480, 511, 428, 528, and 658 bp, respectively (Table 1).
Verification of enrichment was performed by quantitative
PCR on the preamplified ChIP samples. Relative enrichment
was quantified for each site in PCRs using 0.5 ng ChIP DNA or
0.5 ng nonenriched control DNA as template. Of sites identified
by array, 37/40 (93%) of p53-BS and 29/31 (94%) of acetyl H4
sites were confirmed to have enrichment ratios of at least twofold
(Supplemental Fig. 2). These results provide experimental
evidence that very few of the identified sites are false-positives.
As an example, we observed a p53-BS in the first intron of
the TRIM22 gene, which was reported to be p53 regulatedTable 1
Genomic Sites on the ENCODE region Enriched for p53 and Modified Histones
(A) Transcription Start Sites (TSS)
Type # Identified sites Median Size # Sites within 1 kb o
p53 37 (40) 558 (480) bp 2
Acetyl H3 (Lys9/14) 512 511 bp 179
416 428 bp 49
di-Methyl H3 (Lys4) 541 528 bp 222
275 658 bp 175
Type Motif finder c # Sites # Sites with ≥ 1 moti
p53 p53MH 37 23
TRANSFAC 37 29
Acetyl H3 (Lys9/14) p53 512 56
a TSS of RefSeq genes in the UCSC genome browser (hg15).
b Fold-enrichment to the background estimated using 10,000 regions randomly-se
c Two major weight-matrix based programs; p53MH (Hoh, et al., 2002) and TRA(Fig. 2A). A functional p53-response element had been reported
to lie at the region 827 to 846 bp downstream of the TSS of the
gene [31]. Among three p53-binding motifs computationally
found along the gene, our analysis detected one containing the
p53-response element (Fig. 2B), illustrating the advantage of
using an unbiased genomic tiling array for discovery of in vivo
binding sites. Furthermore, in the GeneChip expression analysis,
the expression level of TRIM22was observed to be up-regulated
in a p53-mediated manner, which was not seen in a neighbor
gene, TRIM5 (Fig. 2C). These results indicate that our analysis
identified an authentic p53-BS at high resolution. For further
analysis, we used these 37 p53-BS that were confirmed to have
enrichment ratios of at least twofold.
p53-BS lie throughout the human genome
We examined the identified sites for characteristics asso-
ciated with the cis promoter of the gene. Of the p53-BS detected,
2 (5%), 179 (35%), 49 (12%), 222 (41%), and 175 (64%) of the
p53-binding, acetyl H3, acetyl H4, dimethyl H3, and trimethyl
H3 sites, respectively, were within 1 kb of an annotated
transcription start site (TSS), and their enrichment levels were
approximately 4.1-, 26.6-, 9.0-, 31.2-, and 48.5-fold, respec-
tively, over what would be expected at random (Table 1). These
results indicate that a significant portion of p53-BS were
observed in the regions outside of the cis promoter, which
has been studied extensively as a transcriptional regulatory
region.
We next examined the positions of the identified sites
relative to annotated exons and introns of RefSeq genes. First,
the expected background distribution was generated from
2000 randomly selected regions (Fig. 3). Compared to the
background, the p53-BS showed a slight enrichment at the 5′
and 3′ ends of genes (Fig. 3). However, approximately half
(52%) of the p53-BS were located at the intergenic region
(Fig. 3), indicating the presence of unknown functions of p53
binding at the genomic region that have not been studied
well.
The histone modification sites showed distinctive patterns
of distribution. Whereas the acetyl H4 sites were locatedf TSS a % Sites within 1 kb of TSS a Fold-enrichment b (vs. background)
5 4.1
35 26.6
12 9.0
41 31.2
64 48.5
f % Sites with ≥ 1 motif Fold-enrichment b
62 4.9
78 5.8
11 0.9
lected from the ENCODE region.
NSFAC (Wingerder, et al., 2000).
Fig. 2. A representative p53-binding site. (A) A genomic view of the ChIP-chip result around TRIM5 and TRIM22 (chromosome 11p15.4). Regions enriched for p53,
acetyl H3, acetyl H4, dimethyl H3 (Lys4) and trimethyl H3 (Lys4) are indicated as bars in different colors. One p53-binding site and two acetyl H4 sites are located at
the 5′ end of TRIM22. Acetyl H3, dimethyl H3, and trimethyl H3 sites are observed at the 5′ end of TRIM5. (B) p53-binding motifs found around TRIM22. Sequences
matching the exact consensus are indicated in red. (C) GeneChip expression analysis data for TRIM5 and TRIM 22 in HCT116 (p53+/+) treated with 5FU for 0 to 24 h.
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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acetyl H3 and the di- and trimethyl H3 sites showed a
significant enrichment at the 5′ ends and first introns of
genes (Fig. 3). This suggests the possibility that there are
differential roles for histone modifications in the human
genome.p53-binding motif
The identified p53-BS was searched for the p53-binding
motif by using the motif finder, p53MH [32]. Of 37 p53-BS, 23
(62%) had at least one p53-binding motif meeting a given
significance threshold (Table 1). This is greater than 4.9-fold
Fig. 3. Classification of regions enriched for p53, acetyl H3, acetyl H4, dimethyl H3 (Lys4), and trimethyl H3 (Lys4). For the background estimation, 2000 randomly
selected regions were used. The sites were classified into six groups: within 5 kb of the 5′UTR, within exons, within the first intron, within the other introns, within
5 kb downstream of the 3′UTR of the RefSeq gene, and others (intergenic region).
182 K. Kaneshiro et al. / Genomics 89 (2007) 178–188enrichment over what would be expected at random. By contrast,
the enrichment was not seen for the array-identified acetyl H3
sites (Table 1).
Because a motif finder has its unintentional bias originating
from the learning data set, we also used another weighted-
matrix based motif finder, TRANSFAC [33]. By using
TRANSFAC, 9 other p53-BS were revealed to have at least
one p53-binding motif (Table 1). Thus, in total, 32 (86%) of the
p53-BS had at least one p53-binding motif in their sequences. In
these 32 p53-BS, we found only 1 perfect p53 consensus DNA-
binding motif. This is consistent with the fact that most
preknown p53-BS have a p53-binding motif that is similar but
not identical to the p53 consensus DNA-binding motif.
For five p53-BS lacking an explicit p53-binding motif, we
next searched for other consensus motifs by using the
TRANSFAC weighted-matrixes. This analysis revealed the
enrichment of TBP-, AP1-, and OCT1-binding motifs in these
five regions, with enrichment levels that were 6.5-, 6.3-, and 5.0-
fold, respectively, over what would be expected at random
(Supplemental Table 1).
Furthermore, we compared the DNA-binding activity of p53
between the p53-BS with or without a p53-binding motif by
quantitative PCR. As shown in Supplemental Figure 3, there
was no obvious correlation between the presence of a p53-
binding motif and the fold enrichment of p53.
Histone modification pattern in p53-BS
To elucidate the relationship between the p53-binding and
histone modification, overlap with the histone modification sitewas examined for each p53-BS. The examination was
performed for the region with a fixed length (1.2 kb), spanning
0.6 kb from the center of each p53-BS. Of 37 p53-BS identified,
14 (38%), 33 (89%), 5 (14%), and 1 (3%) overlapped with
acetyl H3 sites, acetyl H4 sites, dimethyl H3 sites, and trimethyl
H3 sites, respectively (Table 2).
We next examined histone modification patterns of the p53-
BS according to their genomic locations relative to annotated
exons and introns of the RefSeq genes. For each genomic
location, the length of p53-BS overlapping with the histone
modification site was summed up. Histone acetylation of the
p53-BS showed distinctive patterns according to the genomic
location (Fig. 4A). Thus, at the 5′ and 3′ ends of genes, 58 and
54% of the p53-BS overlapped with both H3 and H4 acetylation
sites (Fig. 4A). At the other genomic locations, acetylation of
both H3 and H4 was observed for less than 17% of the p53-BS
(Fig. 4A). Interestingly, a significant portion (58%) of H4 acety-
lation in the p53-BS was not accompanied by H3 acetylation.
The H4 acetylation alone of the p53-BS was widely observed at
any genomic location, whereas the H3 acetylation without H4
acetylation was observed at only a small portion of the p53-BS
(Fig. 4A). In contrast, no significant enrichment was observed
for either histone di- or trimethylation of the p53-BS (Fig. 4B).
To explore the p53-dependent kinetics of histone acetylation
at the p53-BS, we compared the fold enrichment of acetylated
histone between TP53 wildtype cells and TP53-null cells by
quantitative PCR. In 4 (36%) of the H3-acetylated regions and
24 (86%) of the H4-acetylated regions, the fold change ratios of
acetylation (TP53 wildtype / TP53-null) were higher than at
least fourfold (Fig. 5). When hierarchically clustered by using
Table 2
List of p53-BS, Histone Modification and Gene Expression Change
ID Chr Start End Fold
enrichment a
Acetyl H3 Acetyl H4 di-Me H3 tri-Me H3 p53 cons. motif Genes b within 5 kb Expression
Change c
1 chr1 147942358 147943557 4.3 + + + + - PIP5K1A I
2 chr2 220512668 220513867 10.5 + + + - + - -
3 chr2 220561677 220562876 16.2 + + - - + - -
4 chr2 234512404 234513603 2 - + - - + - -
5 chr5 55943111 55944310 8.8 - + - - + - -
6 chr5 56086704 56087903 9.8 - + - - + - -
7 chr5 56127634 56128833 4.1 - + - - + - -
8 chr5 131459911 131461110 11.4 - + - - + - -
9 chr5 132165535 132166734 2.6 - - - - + - -
10 chr5 141930795 141931994 8.5 - + - - + - -
11 chr6 41737459 41738658 9.8 - + - - + SNT-2 NC
12 chr7 115440293 115441492 6.3 + + + - + TES I
13 chr7 115464783 115465982 10.3 + + - - + - -
14 chr7 116810368 116811567 10.1 + + - - + CFTR A
15 chr7 116811165 116812364 90.5 + + - - + CFTR NC
16 chr7 126248970 126250169 9.9 - - - - + GRM8 NC
17 chr11 914308 915507 21 - + - - - PYPAF5 A
18 chr11 5669418 5670617 8.6 - + - - - TRIM22 I
19 chr11 5670561 5671760 61.6 - + - - + TRIM22 I
20 chr12 40138437 40139636 19.5 - + - - - SLC2A13 NC
21 chr12 40268988 40270187 6.3 - + - - + SLC2A13 NC
22 chr12 40519961 40521160 26.6 - + - - + - -
23 chr14 52010609 52011808 6.6 - + - - + - -
24 chr14 97787751 97788950 17.3 - + - - + - -
25 chr19 59376460 59377659 9.4 + + - - + LENG5, PRS9 D, I
26 chr20 34563868 34565067 26 + + - - + C20orf44 I
27 chr20 34706768 34707967 47.5 + + - - + CEP2 NC
28 chr20 34707501 34708700 12.3 + + - - + CEP2 NC
29 chr20 34882371 34883570 5.6 - - - - + CPNE1 D
30 chr21 32823527 32824726 8.6 - + - - + - -
31 chr21 34268301 34269500 6.3 - + + - + - -
32 chr21 39285599 39286798 9.6 + + + - + - -
33 chr22 30403435 30404634 8.3 - + - - + MGC50372 NC
34 chr22 30826933 30828132 7.6 - - - - - SLC5A1 A
35 chrX 120904031 120905230 8.9 - + - - + GRIA3 A
36 chrX 151339909 151341108 14 + + - - + G6PD I
37 chrX 151340582 151341781 20.7 + + - - + G6PD I
I: Increased D: Decreased NC: No change A: Absent.
a Fold enrichment quantified by Q-PCR using ChIP DNA and non-enriched input DNA as templates.
b The RefSeq gene in the UCSC genome browser (hg15).
c Change call calculated using a comparative analysis program in the Affymetrix MAS 5.0 package.
183K. Kaneshiro et al. / Genomics 89 (2007) 178–188the enrichment folds of acetyl histone, roughly three patterns of
p53 dependency were observed among the p53-BS (Fig. 5). In
pattern A, p53-dependent acetylation was observed for both H3
and H4. In pattern B, p53-dependent acetylation was observed
only for H4. In pattern C, there was no significant change in
acetylation for either H3 or H4.
Expression change of adjacent gene
To see the relationship between p53 binding and transcrip-
tional regulation, we examined the expression changes of genes
within 5 kb of the p53-BS. GeneChip expression analysis was
performed for RNA prepared from TP53 wildtype cells treated
with 5FU for 0 to 24 h. The expression change was examined
using the comparative analysis program of the Affymetrix MAS
5.0. There was no significant correlation between p53 bindingand the expression change, probably due to a limited number of
genes examined (Table 2). Among 17 genes within 5 kb of the
p53-BS, 6 genes showed an increase and 2 genes showed a
decrease in expression level after the 5FU treatment. There were
no expression changes observed in 6 genes. No expression was
detected at any time point for the rest of genes.Discussion
Novel p53-BS in the human genome
In a 30-Mb portion of the human genome, we found 37 p53-
BS. Extrapolating our results to the whole genome scale
predicts a total of 3700 p53-BS. In the previous ChIP-chip study
of p53 sites along human chromosomes 21 and 22, Cawley et al.
Fig. 4. Histone modification patterns of the p53-BS classified according to their
genomic locations. (A) Histone acetylation pattern. A portion of the p53-BS
observed for both acetyl H3 and acetyl H4 sites is shown in yellow. A portion
observed for only acetyl H3 sites is shown in blue. A portion observed for only
acetyl H4 sites is shown in red. A portion observed for neither acetyl H3 nor H4
is shown in gray. (B) Histone methylation pattern. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version
of this article.)
Fig. 5. Differential patterns of the p53 dependency of histone acetylation at the
p53-BS. For each p53-BS, a fold enrichment against the input DNA was
measured by quantitative PCR for acetyl H3 and acetyl H4 in HCT116 (p53+/+)
and HCT116 (p53−/−). The fold enrichment was scaled with dark and light
coloring. Those sites not observed for acetylation by arrays were indicated as N.
D. (not detected). Nodes of the tree are designated A, B, and C.
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be attributable to the different cellular stresses used for p53
activation. We used 5FU as a DNA-damaging agent, whereas
Cawley et al. used bleomycin. As with Cawley et al.’s report,
the p53-BS identified in this study lie throughout the human
genome, including exons and introns of annotated potential
gene targets and uncharacterized intergenic regions. Recently,
the p53-BS was determined by a method combining ChIP and
paired-end di-tag (PET) sequencing [34]. Comparing our data
with the PET-2 data released at the University of California at
Santa Cruz (UCSC) database, 9 (24%) p53-BS were concordant
with our results. The other p53-BS have not been described
previously.
Of 37 p53-BS, 30 (81%) had at least one p53-binding
consensus motif in their sequences, whereas 7 (19%) had no
explicit p53-binding motif. Those TF-BS lacking a consensus
binding motif were also reported in the previous genome-wide
studies for other TFs, such as RELA, GATA1 and CREB1
[35–37]. Interestingly, in the 7 p53-BS lacking a p53-binding
motif, we found enrichment of other TF-binding motifs, such
as the EGR family, TBP, and CREB1. Physical interaction of
p53 with EGR1 and TBP has been reported [38,39]. p53 has
been reported to interact with CREB1 via binding to the KIX
domain of EP300 [40]. These data raise the possibility thatother DNA-binding proteins may mediate indirect interactions
between p53 and DNA.
We examined the DNA-binding activity at each p53-BS by
measuring a relative enrichment of the identified site with
quantitative PCR using ChIP DNA and nonenriched input DNA
as a template. Enrichment levels were variable and seemed to
have no correlation with the presence of a p53-binding motif.
Also, there was no significant correlation with the genomic
location of p53-binding (data not shown), suggesting that the
DNA-binding activity of p53 in vivo is determined by factors
other than the number or location of the p53-BS.
Although p53 is typically described as a transcriptional
regulator, many genes within 5 kb of p53-BS did not show any
significant change in their expression levels, suggesting that
there must be additional factors required for transcriptional
regulation, such as cofactors, histone modification, and
demethylation of DNA.
185K. Kaneshiro et al. / Genomics 89 (2007) 178–188Discrete pathways for histone acetylation and histone
methylation
Histone tails are the target of a variety of covalent modi-
fications. Among the many possible modifications of histone
tails, di- and trimethylation of histone H3-K4 and acetylation of
histone H3-K9/14 and H4-K5/8/12/16 are well documented to
be correlated with actively transcribed regions [41]. In this
study, we focused on the relationship between p53 binding and
these histone modifications.
Although p53 forms protein complexes containing both
histone acetyltransferases and methyltransferases, p53 binding
was strongly associated with histone acetylation, rather than
histone methylation. Among several protein methyltransferases,
SETD7 is known to interact with p53 and target H3-K4 in vitro
[42]. However, a recent study has revealed that purified SETD7
has no catalytic activity for histone H3-K4 assembled into
nucleosomes, which are thought to be the physiologically
relevant substrates for chromatin-modifying enzymes [43].
Collectively, the evidence suggests that there are other p53-
independent factors necessary for histone methylation in vivo,
and p53 itself mainly mediates histone acetylation via
recruitment of histone acetyltransferases to target sites.
Distinctive patterns of histone acetylation in the p53-BS
according to the genomic locations relative to the gene
structure
When we classified the p53-BS into several groups
according to the location relative to annotated exons and
introns of RefSeq genes, differential patterns of histone
acetylation were observed among the groups. The acetylation
of H3 was often observed in the 5′ ends and 3′ ends of genes,
whereas the acetylation of H4 was observed at any genomic
location. Recent comparative genomic studies have reported
that noncoding sequences located at the 5′ and 3′ ends of genes
are often conserved among species and have some roles in
transcriptional regulation [44]. The biased distribution of
histone acetylation suggests the generation of noncoding
transcripts in these genomic regions. However, it is still unclear
whether those transcripts participate in p53-regulated functions.
One possible explanation for the differential pattern in the
acetylation of H3 and H4 is the presence of variants in H3. Four
different isoforms of H3 have been reported: H3.1, H3.2, H3.3,
and CENPA [45]. In Drosophila cells, H3.3 is known to be
present at transcriptionally active loci [46]. The deposition of
H3.3 occurs replication-independently, and some histone
modifications have been shown to be restricted to nucleosomes
containing H3.3 [47]. Such a nucleosome variant might
account for the distinctive distribution of histone acetylation.
Although it is still unclear whether these histone acetylations
can be set prior to p53 binding, we provide evidence for the p53
dependency of these changes in the chromatin state. In TP53-
null cells, histone acetylation was observed at only a few of the
p53-binding regions detected in TP53 wildtype cells. However,
it remains unknown how p53 can recognize its binding
sequence in condensed chromatin.Conclusion
Here we have presented an integrated map of p53 binding
and histone modification along 30 Mb of the human genome at
high resolution. Novel p53-BS were found throughout the
genome and showed various features with respect to density,
genic location, and the presence or absence of consensus p53-
binding motifs. Our analysis also revealed distinctive patterns of
histone modification in the p53-BS according to location
relative to gene structures. The combination of these various
factors might account for the great diversity of p53-binding sites
in the genome and provide a physical basis for the broad range
of p53-regulated transcriptional programs in humans. On the
other hand, we did not observe a significant correlation between
p53 binding and the expression of adjacent genes, probably due
to a limited number of targets examined. To better elucidate the
mechanisms underlying the complex transcriptional regulation
by p53, further large-scale genomic studies are required.
Materials and methods
Cell culture, cell extracts, and Western blotting
HCT116 cells (TP53-wild-type+/+) and TP53-null derivatives were dis-
tributed from Professor Bert Vogelstein (Johns Hopkins University), grown in
MacCoy’s 5A medium supplemented with 10% FBS at 37, in a humidified
atmosphere with 5% CO2. p53 was induced by treatment with 375 μM5FU for 0
to 24 h. The cells were washed in Dulbecco’s phosphate-buffered saline and
harvested in lysis buffer [50 mMTris (pH 8.0), 150 mMNaCl, 1 mM EDTA, 1%
Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, 10 mM NaF, and 2 mM
Na3VO4] containing protease inhibitors (Sigma). Lysates were maintained at 4
for 30 min followed by spin centrifugation for 15 min at 15,000g. Supernatants
were collected and boiled with 2× SDS sample buffer. Immunoblotting was
performed as previously described [48]. Antibodies used were p53 (FL-393),
p21 (C-19), and MDM2 (SMP-14) from Santa Cruz (California, USA) and
phosphorylated p53 (Ser15), phosphorylated p53 (Ser20), and acetylated p53
(Lys382) from Professor Youichi Taya (National Cancer Center, Japan).
RNA extraction and microarray expression analysis
Total RNA was extracted with the use of Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. The experimental procedures for
GeneChip (Affymetrix, Santa Clara, CA) were performed according to the
Affymetrix GeneChip expression analysis technical manual. Briefly, 10 μg of
total RNA was used to synthesize biotin-labeled cRNA, which was then
hybridized to a GeneChip Human U133 plus 2.0 oligonucleotide array
(Affymetrix). After being washed, the arrays were stained with streptavidin–
phycoerythrin and analyzed on a Affymetrix scanner to collect the image data.
Microarray Suite software 5.0 (Affymetrix) was used to calculate the average
difference (AD) for each gene probe set, which was shown as an intensity
value of the gene expression. The AD values were normalized for each array so
that the average of all AD values was 100. For expression change calls, we
used the comparative analysis (Wilcoxon signed-rank test-based analysis)
program in the Microarray Suite 5.0 software. The analysis was performed
with the default parameters, where the p value for significant difference was
below 0.0025. For details, please refer to Statistical Algorithms Reference
Guide available at the website http://www.affymetrix.com/support/technical/
technotes/statistical_reference_guide.pdf. Raw data are available at the website
http://www.genome.rcast.u-tokyo.ac.jp/Tiling_Array/.
Chromatin immunoprecipitation
HCT116 cells (p53+/+, p53−/−) were cultured in 15-cm plates to approximately
70 to 80% confluence, and 5 plates were used per immunoprecipitation. For p53
186 K. Kaneshiro et al. / Genomics 89 (2007) 178–188induction, cells were treated for 9 h with 375 μM 5FU dissolved in dimethyl
sulfoxide. Cells were fixed with 1% formaldehyde for 10 min at room temperature,
with occasional swirling. Glycine was added to a final concentration of 0.2 M and
the incubation was continued for an additional 5 min. Cells were washed with ice-
cold PBS, harvested by scraping, pelleted, and resuspended in SDS lysis buffer
[10 mM Tris-Cl (pH 8.0), 150 mM NaCl, 1% SDS, 1 mM EDTA]. Samples were
sonicated with TomyUD-201 for 5 cycles of 1 min (60% duty, output level 2) with
an interval of 1 min. Then, samples were centrifuged at 13,000g at 4 for 10 min and
diluted fivefold in ChIP dilution buffer [20 mM Tris-Cl (pH 8.0), 150 mM NaCl,
1mMEDTA, 1%TritonX-100, and protease inhibitors]. After removal of a control
aliquot (whole-cell extract), samples were incubated at 4 overnight with 50 μl
protein A–Sepharose beads that had been incubated overnight with 5–10 μg
antibodies against p53 (FL393, Santa Cruz), acetyl H3 Lys9/14 (Upstate), and
acetyl H4 Lys5/8/12/16 (Upstate). After being washed, the immunoprecipitated
materials were eluted from the beads by heating for 30 min at 65 in elution buffer
[25 mM Tris-Cl (pH 7.5), 10 mM EDTA, 0.5% SDS]. The cross-links were then
reversed with incubation with 1.5 μg/ml Pronase at 42 for 2 h followed by
heating at 65 overnight. The DNA was extracted with a PCR purification kit
(Qiagen).
Quantitative PCR
Quantitative PCR was performed using an iCycler iQ Detection System
(Bio-Rad, Hercules, CA). Reaction mixtures contained SYBR Green I
fluorescence (BMA, Rockland, ME) and primers as follows: for CDKN1A,
GTGGCTCTGATTGGCTTTCTG (forward) and CTGAAAACAGGCAGCC-
CAAG (reverse). PCR conditions were as follows: 1 cycle of 94 for 3 min
followed by 40 cycles at 94 for 30 s, 65 for 30 s, 72 for 1 min, and detection (85
for 10 s). All the samples were run in triplicate and the results were averaged.
DNA amplification and array hybridization
ChIP DNA samples were amplified by two cycles of IVT. The first cycle of
the IVT amplification was performed as described [23]. The amplified RNAwas
converted into single-strand cDNA with random primers, annealed with T7
primer followed by second-strand cDNA synthesis, and amplified again by in
vitro transcription using the T7 Megascript Kit (Ambion) according to the
manufacturer’s instructions. A second amplified RNA was converted into
double-strand cDNAwith random primers, fragmented with DNase I, and end-
labeled with biotin as described [51]. Two microgram samples of ChIP and
control (whole-cell extract) were hybridized on the separate Affymetrix
ENCODE 01 oligonucleotide arrays. Arrays were hybridized for 16 h at 45,
washed using the antibody amplification protocol described in the Affymetrix
Expression Analysis Technical Manual, and scanned using an Affymetrix Gene
Array scanner. For p53, acetyl H3 and acetyl H4, two biologically independent
ChIP samples were amplified in triplicate and hybridized individually. For
di- and trimethyl H3, three biologically independent ChIP samples were
individually amplified and hybridized. Raw data are available at the website
http://www.genome.rcast.u-tokyo.ac.jp/Tiling_Array/.
Analysis of tiling array data
Raw array data were quantile normalized within enriched and control
replicate groups [49]. (PM, MM) intensity pairs were mapped to the genome
using exact 25-mer matching hs.NCBIv33. For each genomic position to which
a probe pair mapped, a data set was generated consisting of all (PM, MM) pairs
mapping within a window of +/− 275 bp. A Wilcoxon ranked-sum test was
applied to the transformation log2[max(PM-MM, 1)] for data from the six
treatment and six control DNA arrays, testing the null hypothesis that treatment
and control data come from the same probability distribution. For each window,
a signal ratio was also estimated by the Hedges-Lehmann method computing the
median of fold enrichment among the probe sets within the window.
Sequence analysis
The sequences of human RefSeq transcripts (hg16) were downloaded from
the UCSC genome browsers (http://www.genome.ucsc.edu/). For each array-identified site, overlap with the transcripts was judged at a base to base level.
Enrichment analysis of consensus binding motifs was performed with the
position-weighted matrix (PWM) method. PWM matrixes were retrieved from
TRANSFAC and the p53MH program. The threshold score of each motif was
calculated with p<10−4 in the background genome, where the motif was found
approximately once in 10 kb.
Hierarchical clustering
The hierarchical clustering was performed using Eisen’s cluster program
[50]. The fold enrichment of each acetylated histone was log-transformed and
clustered with an algorithm of correlation (uncentered).
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